The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma who have received one to three lines of therapy. Darzalex Faspro is a subcutaneous, or under-the-skin, formulation…
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study found. The study, “Effect of the…
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent bone problems — such as fractures, spinal cord compressions, and the need for radiation or surgery — in people with…
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to be manufactured was found to be safe and did not impact CAR T-cell therapy, a small study reports. …
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with triple-refractory multiple myeloma to access the investigational medicine melflufen (melphalan flufenamide) before its approval. …
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European…
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines, a large review study reports. Older patients and those with low-risk disease show the greatest gains…
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a study reported. This therapy targets a protein called CD229, produced on the surface of both myeloma…
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple myeloma patients included in the DREAMM-2 trial, the company announced. Findings from the open-label DREAMM-2 study (NCT03525678) — which is assessing two different…
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma throughout 2019. As a reminder of what mattered most to you in 2019, here are the top 10 most-read articles of last year with a…
Get regular updates to your inbox.